🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to researchers.

An International Challenge

Cases of gonorrhoea are increasing worldwide, with data suggesting more than 82 million new cases each year. Particularly high rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, the spread of superbugs and the very limited therapeutic options at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Secure Clearance

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in mid-December for use against gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone marks a significant shift in the therapy of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Clinical Trial Results and Global Access

According to findings released by a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which involves a dual-drug approach. The trial involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared hope. The availability of a one-pill regimen of this kind is hailed as a "critical tool" for public health efforts. This is viewed as essential to lessen the impact of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.